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OBJECTIVES: Fallopian tubes are commonly removed during laparoscopic and open hysterectomy to prevent ovarian and tubal cancer, but not routinely removed during vaginal hysterectomy due to assumed increased morbidity. We sought to quantify complications and costs associated with a strategy of planned salpingectomy with vaginal hysterectomy.
MATERIALS AND METHODS:
We created a decision analysis model using TreeAgePro (TreeAge Software Inc.; Williamstown, MA). Figure 1 represents a simplified diagram of our decision tree. Effectiveness outcomes included ovarian cancer incidence and mortality as well as major surgical complications. Modeled complications included transfusion, conversion to laparotomy or laparoscopy, abscess/hematoma requiring intervention, ileus, readmission, and reoperation within 30 days. We also modeled subsequent benign adnexal surgery beyond the postoperative window. Those whose procedures were converted from a vaginal route were assumed to undergo salpingectomy regardless of treatment group, following ACOG guidelines. Costs were gathered from published literature and Medicare reimbursement data, with internal cost data from 892 hysterectomies used to estimate costs when necessary. Complication rates were determined from published literature and from 13,397 vaginal hysterectomies recorded in the National Surgical Quality Improvement Program database from 2008-2013. RESULTS: Switching from a policy of vaginal hysterectomy alone to a policy of routine planned salpingectomy prevents 1 in 225 ovarian cancer cases, and 1 in 450 ovarian cancer deaths. Overall, salpingectomy was a less expensive strategy than not performing salpingectomy ($7,350.62 vs. $8,113.45) . This effect persisted when costs of treating cancer were excluded from the analysis ($6,860.87 vs. $7,197.08 ). This second analysis was performed as we wanted to ensure the high costs of treating cancer were not skewing our results. Given that salpingectomy is both more effective and has lower cost, it is considered the "dominant" strategy and further cost-effectiveness analysis with incremental cost effectiveness ratios and willingness to pay thresholds is unnecessary. Sensitivity analysis demonstrated the driving force behind increased costs was the increased risk of subsequent benign adnexal surgery among women retaining their tubes. We therefore performed an additional analysis where subsequent benign adnexal surgery was removed from the model to eliminate the impact of that variable. Salpingectomy became the more expensive strategy when cancer treatment costs were also excluded. In this secondary analysis, it costs $1,196.99 to prevent 1 case of cancer. Planned opportunistic salpingectomy had more major complications than hysterectomy alone (7.95% vs. 7.68%). Therefore, routine salpingectomy results in 0.61 additional complications per case of cancer prevented and 1.21 additional complications per death prevented. CONCLUSION: Salpingectomy should routinely be performed with vaginal hysterectomy as it was the dominant and therefore costeffective strategy. Complications are minimally increased, but the trade-off with cancer prevention is highly favorable.
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12 Prophylactic salpingectomy during vaginal hysterectomy: A feasibility study 
OBJECTIVES:
The American Congress of Obstetricians and Gynecologists (ACOG) recommends that "the surgeon and patient should discuss the potential benefits of the removal of the fallopian tubes during a hysterectomy in women at population risk of ovarian cancer who are not having an oophorectomy," resulting in an increasing rate of salpingectomy at the time of hysterectomy. Rates of salpingectomy are highest for laparoscopic (>60%) and lowest for vaginal (<20%) hysterectomy. The objectives of this study were to determine whether bilateral salpingectomy is feasible in the majority of planned vaginal hysterectomies and to assess its impact on operating time, estimated blood loss (EBL), surgical complications, and menopausal symptoms. MATERIALS AND METHODS: This was a multicenter, prospective, observational study of patients undergoing planned vaginal hysterectomy with bilateral salpingectomy. At baseline, demographic and relevant medical data were collected. Surgical procedure, intraoperative findings, operative time, and EBL for salpingectomy were recorded. Uterine weight and pathology reports for all fallopian tubes were reviewed. Patients completed the Menopause Rating Scale (MRS) at baseline and at post-operative follow-up (6-12 weeks). Descriptive analyses and logistic regression were performed to characterize the sample and identify factors associated with Oral Presentations ajog.org non-completion of planned salpingectomy. MRS scores were compared using paired t-tests. RESULTS: Among 70 patients offered enrollment in this study, 67 (96%) consented, and complete data are available for 62 (93%). Mean age was 51.1 years (AE 9.4). Median body mass index (BMI) was 27.1 kg/m2; median vaginal parity was 2 (0-4), and 43% were postmenopausal. The primary indication for hysterectomy was prolapse (76%), heavy menstrual bleeding (18%), and other (6%). Vaginal salpingectomy was successfully performed in 46/62 (74%) women. Mean operating time for bilateral salpingectomy was 11 minutes (AE 5.7), with additional mean EBL of 6 cc (AE 17.3). There were 8 surgical complications: 3 hemorrhages > 500 ml and 5 conversions to alternate routes of surgery, but none of these were due to the salpingectomy. Mean uterine weight was 68 grams and there were no abnormalities on fallopian tube pathology. Among the 16 patients in whom planned bilateral salpingectomy was not completed, unilateral salpingectomy was performed in 6 and both tubes were left in situ in 10. Reasons for non-completion of salpingectomy included: tubes were too high in the pelvis (7), conversion to alternate route for pathology (2), ovarian adhesions (2), bowel or sidewall adhesions (3), no reason (1), and ovarian pathology requiring oophorectomy (1). There were no identified risk factors for unsuccessful salpingectomy including age (p ¼ 0.05), BMI (p ¼ 0.68), and prior tubal ligation (p ¼ 0.052). Mean MRS scores did not significantly change from preoperatively to postoperatively (9.85 vs 6.04, p ¼ 0.61). CONCLUSION: Vaginal salpingectomy is feasible in the majority of women undergoing planned vaginal hysterectomy and increases operating time by 11 minutes and EBL by 6 cc. Risk factors for unsuccessful removal could not be identified.
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OBJECTIVES: Many gynecologic, urologic and pelvic reconstructive surgeries require accurate intra-operative evaluation of ureteral patency. The objective of this study is to compare surgeon satisfaction with four methods of evaluating ureteral patency at the time of cystoscopy: phenazopyridine, sodium fluorescein, mannitol, and normal saline.
MATERIALS AND METHODS:
We conducted a randomized controlled trial of the method used to evaluate ureteral patency during cystoscopy at time of benign gynecologic or pelvic reconstructive surgery. Subjects were randomized to 200 mg oral phenazopyridine, 25 mg sodium fluorescein intravenously, mannitol bladder distention, or normal saline bladder distention during cystoscopy to evaluate ureteral patency. The primary outcome was surgeon satisfaction with the method, which was assessed via a 10 cm Visual Analog Scale (VAS). A priori sample size of 137 participants was planned to detect a 3 cm difference in the VAS scale with 80% power and a 2-tailed alpha of 0.05, including 10% added for participant dropout. Demographic and operative information, including time to confidence in the ureteral jets was collected. Adverse events were followed for at least 6 weeks after the surgical procedure. RESULTS: Two hundred nine patients were screened for eligibility, 193 met inclusion criteria, and 140 were consented and enrolled in the study. One hundred thirty subjects were randomized and evaluated according to intention-to-treat into four groups: phenazopyridine (n ¼ 33), sodium fluorescein (n ¼ 32), mannitol (n ¼ 32), and normal saline (n ¼ 33). Demographics were similar between groups with mean/standard deviation age of 50 years (12) and BMI 29 (7), and median/range parity 2 (0, 8). Forty-two percent were Hispanic, 31% white, 19% African American, 2% Asian, and 6% unknown/other. Indications for surgery were similar across groups and included AUB/fibroids (48%), prolapse (28%), incontinence (12%), and microhematuria (4%). Type of surgery did not differ across groups and included 55% hysterectomy, 42% pelvic reconstruction, and 26% incontinence surgery. With regard to the primary outcome, mannitol was noted to be the most satisfactory method to physicians for assessing ureteral patency (p < 0.001). Mannitol was also the easiest method to use and the agent that provided the clearest and most definitive visualization of the ureteral jets, bladder mucosa and urethra (all p < 0.001). Surgery length, cystoscopy length, and time to confidence in ureteral jets were not different between groups (all p > 0.05). During the 111 day median followup, there was no significant difference in adverse events noted among the groups, including urinary tract infections (all p > 0.05). CONCLUSION: The use of mannitol during cystoscopy to assess ureteral patency provided surgeons with the most overall satisfaction, ease of use, and superior visualization without impacting surgery or cystoscopy times. There were no differences in adverse events, including urinary tract infections.
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14 Impact of liposomal bupivacaine on pain following retropubic midurethral sling placement: A randomized placebo-controlled trial OBJECTIVES: Midurethral slings are commonly used to treat stress urinary incontinence. Pain control, however, may be a concern. We sought to examine the impact of liposomal bupivacaine (LB), a local anesthetic with slow release over 72 hours, on pain scores following retropubic midurethral sling placement. MATERIALS AND METHODS: This randomized, placebo-controlled trial enrolled women undergoing retropubic midurethral slings with or without concomitant anterior or urethrocele repair under general anesthesia. Subjects were allocated to receive LB or normal saline placebo (P) injected into the trocar paths and vaginal incision at the
